奥氮平联合托烷司琼、地塞米松预防高致吐风险药物化疗引起恶心、呕吐的疗效分析

目的 观察奥氮平联合托烷司琼、地塞米松预防高致吐风险药物化疗引起恶心、呕吐的临床疗效和不良反应。方法 采用含高致吐风险药物化疗的78例患者随机分为观察组(奥氮平联合托烷司琼、地塞米松)和对照组(托烷司琼联合地塞米松),观察各组化疗后恶心、呕吐等不良反应的发生情况。结果 观察组与对照组防治急性呕吐的有效率分别为87.5%和81.6%,观察组与对照组防治急性恶心的有效率分别为65.0%和57.9%,差异均无统计学意义(P>0.05);观察组与对照组防治迟发性呕吐的有效率分别是75.0%和52.6%,观察组与对照组防治迟发性恶心的有效率分别为32.5%和13.2%,差异均有统计学意义(P<0.05)。两组间不良反应发生率比较,差异无统计学意义(P>0.05)。结论 奥氮平联合托烷司琼、地塞米松预防高致吐风险药物化疗所致迟发性恶心、呕吐疗效显著,不良反应轻。

Efficacy of Olanzapine Combined with Tropisetron, Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-induced Nausea and Vomiting

Objective To observe the efficacy and side effect of olanzapine combined with tropisetron, dexamethasone for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting (CINV). Methods A total of 78 patients with highly emetogenic single day chemotherapy were randomly divided into two groups: trial group (olanzapine combined with tropisetron, dexamethasone n=40) and control group (Tropisetron Combined with Dexamethasone n=38).The control of acute CINV, delayed CINV and adverse reactions were observed. Results The control rates of acute vomiting in trial group and control group were 87.5% vs 81.6%, 65.0% vs 57.9% in acute nausea, 75.0% vs 52.6% in delayed vomiting, 32.5% vs 13.2% in delayed nausea. The trial group was better than the control group in delayed vomiting and delayed nausea which there was difference between them (P<0.05). There was no statistical difference between the two groups in the incidence of adverse reactions (P>0.05). Conclusion Olanzapine combined with tropisetron, dexamethasone for the prevention was significantly better than tropisetron combined with dexamethasone in the control of delayed CINV in patients received highly emetogenic chemotherapy.